Longboard Pharmaceuticals Inc is a biotechnology business based in the US. Longboard Pharmaceuticals shares (LBPH) are listed on the NASDAQ and all prices are listed in US Dollars. Longboard Pharmaceuticals employs 6 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $4.45 |
|---|---|
| 52-week range | $4.01 - $18.95 |
| 50-day moving average | $5.41 |
| 200-day moving average | $8.18 |
| Wall St. target price | $29.75 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.62 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.45 from 2022-01-25
| 1 week (2022-01-19) | -6.71% |
|---|---|
| 1 month (2021-12-23) | -17.59% |
| 3 months (2021-10-26) | -44.10% |
| 6 months (2021-07-26) | -49.43% |
| 1 year (2021-01-22) | N/A |
|---|---|
| 2 years (2020-01-22) | N/A |
| 3 years (2019-01-22) | N/A |
| 5 years (2017-01-22) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | 0% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | $6.62 |
| Market capitalisation | $74.7 million |
TTM: trailing 12 months
We're not expecting Longboard Pharmaceuticals to pay a dividend over the next 12 months.
You may also wish to consider:
Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Strategies to help you make the most of your retirement savings.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
These five bank stocks are leading the financial sector as it rises in response to higher interest rates expected from the Fed.
Retailers see fewer-than-expected sales as Omicron empties stores and drives labor shortages. How far will the stocks slip?